In August, several outlets reported early results from a UCSF trial suggesting cannabis use days looked no worse, and maybe a little better, for heart rhythm than abstinence days. We covered that early signal ourselves, twice, working from secondhand summaries with no DOI, no trial ID, and no peer review yet attached.

That gap is now closed. The full study, Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose, by Elias and colleagues at UCSF, is published in the Journal of the American College of Cardiology, with exact effect sizes, confidence intervals, and a same-issue editorial urging restraint in how the finding is used. That combination, a real effect cleanly reported with a built-in caution flag from the journal itself, is exactly the kind of evidence worth walking through carefully rather than repeating as a headline.

Most of what we know about cannabis and heart rhythm comes from observational data, the kind that can’t separate cause from coincidence. This trial is different: participants served as their own controls, randomly assigned to use or abstain on different days over two weeks, wearing a continuous heart monitor the whole time. That design is what lets us say the 9% reduction in ectopic beats is a real, measured association within this study, not just a pattern someone noticed after the fact.

For patients who already worry that their cannabis use is causing palpitations, that is a genuinely useful data point in a cardiovascularly healthy population like the one studied here, an increase in ectopy on cannabis days is not what the best current randomized evidence shows.

The authors’ own discussion, and the entire premise of the accompanying editorial, is a caution against reading this as “cannabis protects the heart.” A crossover trial in habitual users compares cannabis days to abstinence days within the same person. The more parsimonious explanation for fewer ectopic beats on use days is that abstinence itself provoked more ectopy, plausibly through withdrawal-related autonomic or sympathetic activation in people accustomed to regular use, not that inhaled cannabis has a protective cardiac effect in any general sense.

The authors are explicit about this: they describe “potential withdrawal effects, moderate adherence, and co-intervention” as limiting factors on causal interpretation. Adherence to the randomized schedule was imperfect. And the population was pre-selected to be low risk: no arrhythmia history, no antiarrhythmic drugs, no implanted devices, no insulin use. None of that makes the result wrong; it makes it narrow, and narrow results get misread the moment they leave the paper.

This finding does not contradict the separate, larger body of observational evidence linking heavier, longer-term cannabis use to higher rates of atrial fibrillation and cardiovascular events. Those studies are asking a different question over a different timescale: cumulative, chronic exposure and structural or vascular risk, while MARY-JANE asked about acute, day-to-day rhythm effects in people who were already regular users and already cardiovascularly healthy.

Both things can be true at once: acute inhalation may not provoke more ectopy on the day of use in a low-risk habitual user, while sustained heavy use over years still carries measurable cardiovascular risk in the population as a whole. Patients, and the headlines built for them, tend to flatten that distinction into a single verdict. It is worth not doing that here.

After more than 300,000 patient encounters in cannabis medicine, the question I hear most about the heart isn’t “will this hurt me long-term”; it’s “why do I feel palpitations, and is it the cannabis.” This trial is a genuinely useful data point for that specific, common conversation, in patients who are otherwise healthy: it does not support blaming acute use for new ectopy, and it flags that quitting itself may come with a rhythm-related adjustment worth naming in advance.

What it changes nothing about is the patient in front of me with known arrhythmia, a device, or antiarrhythmic medication: this trial simply doesn’t apply for that patient, because it was designed not to include them. The editorial’s title is the right instruction here: take nothing for granted, in either direction.

A well-designed randomized trial found a small, real reduction in ectopic heartbeats on cannabis-use days versus abstinence days, in healthy habitual users, most plausibly reflecting a withdrawal effect of abstinence rather than a cardioprotective effect of cannabis. The finding is reassuring for a narrow, common clinical question and irrelevant to patients with existing heart rhythm disease, who were excluded from the trial entirely.